Identification of resistance mechanisms to EGFR treatment in the real world using a clinicogenomic database Published April 2018 Citation Singal, G, Li, G, Agarwala, V, Kaushik, G, O’Connell, C, Alpha-CobbG, Caron, T, Bourque, D, Guria, A, Frank, S, Frampton, G, Carson, K, Abernethy, A.P., Miller, V.A. . AACR Annual Meeting. . https://4076230.fs1.hubspotusercontent-na1.net/hubfs/4076230/flatiron-com-pdf/AACR-2018-FH-FMI-CGDB-Poster-180411.pdf Authors: Sources:American Association for Cancer Research Annual Meeting Share Posted inPublicationsDrug discovery More publicationsESMO OpenSeptember 2025Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practiceRugo H, Layman R, Lynce F, et al.Publication summaryPublicationsComparative effectivenessMetastatic breast cancerBreast cancerWorld Conference on Lung CancerAugust 2025Disease burden and rwPFS as a surrogate endpoint for rwOS in NTRK+ NSCLC and other advanced/metastatic solid tumorFlores Avile C, Su I-H, Huang P-C, Cho-Phan C, Camidge R, Yuan Y.Publication summaryPublicationsNon-small cell lung cancerWorld Conference on Lung CancerAugust 2025Evolving treatment patterns in early-stage non-small cell lung cancer in the USGray J E, Thoele K, Gilligan A M, et al.Publication summaryPublicationsTreatment patternsNon-small cell lung cancer